Which patients receiving mosunetuzumab need particular monitoring for tumour lysis syndrome?

All patients receiving mosunetuzumab (Lunsumio) should be monitored for tumour lysis syndrome, especially those with high tumour burden, rapidly proliferative tumours or reduced renal function.